Citicoline vs Alpha-GPC
By Peter Benson, Cognitive Enhancement Researcher · Updated October 2026 · Citations re-verified
Short answer: Neither citicoline nor alpha-GPC has strong evidence in healthy adults. Citicoline has one positive 12-week memory trial in older adults, funded by its maker. Alpha-GPC has one small single-dose trial, and two large observational studies disagree on whether it raises stroke risk. If you want one, citicoline is the more cautious choice.
⚕️ Educational information, not medical advice — full disclaimer. This page contains two affiliate links, both in the buying section.
Citicoline or alpha-GPC is the question I get more than any other about choline supplements. Most comparisons pick a winner on mechanism: alpha-GPC for its higher choline content, citicoline for its extra cytidine pathway. The human trials don’t support a confident winner. Both compounds were tested mostly in people with dementia or stroke, both have very little data in healthy adults, and the three trials that compared them directly used injections, not capsules.
So this article sets the two evidence bases side by side, covers the stroke-risk question that hangs over alpha-GPC, and then gives a recommendation anyway. For more on one compound, see the full alpha-GPC guide; for the wider picture, the Nootropics & Supplements guide.
Citicoline vs alpha-GPC: which is better?
Only three trials have compared them directly, and a 2025 meta-analysis pooled them: 358 people with vascular or multi-infarct dementia, average age about 69. Alpha-GPC came out ahead on an overall clinical rating scale and on its cognitive, mood and apathy sub-scores. There was no significant difference on a memory test or a word-fluency test, and dropout rates were similar (Sagaro & Amenta, 2025).
Three things limit what that tells a supplement buyer. Every trial gave both compounds by intramuscular injection, at 1,000mg a day for three months, so none of them tested a capsule. All three date from the early 1990s and were rated at high risk of bias because participants and assessors were not blinded. And everyone studied had dementia. The authors themselves describe the evidence as few studies of low methodological quality.
For a healthy adult choosing a capsule, there is no direct comparison at all. The choice has to be made from each compound’s separate evidence, and from the safety difference between them.
How citicoline and alpha-GPC differ
Both supply choline, which the body uses to make the neurotransmitter acetylcholine and the membrane phospholipid phosphatidylcholine. Alpha-GPC is a choline-containing phospholipid that is roughly 40% choline by weight. Citicoline is broken down into choline and cytidine, and carries about half as much choline per milligram. The cytidine half is converted to uridine, which feeds the pathway that builds phosphatidylcholine. That second route is citicoline’s distinctive feature and the usual explanation for its use in neurological conditions.
Two cautions about reading too much into the chemistry. First, more choline per capsule is not the same as more benefit: the US Office of Dietary Supplements notes that a systematic review of 13 studies found choline supplements did not clearly improve cognition in healthy adults. Second, when the European Food Safety Authority assessed citicoline in 2024, it judged the evidence for a biological mechanism behind a memory benefit to be insufficient.
Then there is the claim that alpha-GPC is “more bioavailable.” The study usually cited is Gatti and colleagues (1992), who measured plasma choline in 12 volunteers after 1,000mg of each compound given by intramuscular injection. Alpha-GPC raised plasma choline considerably more. An injection bypasses digestion and the liver, so this says little about a swallowed capsule. No oral head-to-head has been done.
Alpha-GPC: what the human trials show
Alzheimer’s disease and mild cognitive impairment
The best-known trial is a multicentre, double-blind, placebo-controlled study in mild-to-moderate Alzheimer’s dementia at 400mg three times a day, which reported cognitive improvement over placebo (De Jesus Moreno Moreno, 2003). The Alzheimer’s Drug Discovery Foundation notes that the participants were not taking current Alzheimer’s medicines, and that later results on adding alpha-GPC to those medicines have not been confirmed.
A newer trial is closer to the kind of person who buys a supplement. In 100 adults aged 55 to 85 with amnestic mild cognitive impairment, 600mg once a day for 12 weeks lowered the ADAS-cog score by 2.34 points, significantly more than placebo, with no serious adverse events (Jeon et al., 2024). The trial was supported by Suheung and used a branded capsule. Twelve weeks is short, and people with diagnosed impairment are not healthy adults.
Healthy adults
There is one relevant trial. Twenty resistance-trained men took placebo, 315mg or 630mg in a randomised, double-blind crossover and were tested 60 minutes later. Stroop performance improved, most clearly at the higher dose. The Flanker and N-back tests showed no significant difference (Kerksick, 2024). The study was funded by an alpha-GPC supplier, and its author is a paid scientific adviser to that company.
In practice: one positive test out of three, in 20 young men, after a single dose, in a sponsor-funded study. That is a reason for another trial, not a demonstrated benefit. Nothing shows what daily use does to cognition in healthy people.
Citicoline: what the human trials show
Healthy and older adults
The strongest study is a randomised, double-blind trial in 100 adults aged 50 to 85 with age-associated memory impairment. Those taking 500mg a day for 12 weeks improved more than placebo on episodic memory and on a composite memory score (Nakazaki et al., 2021). The trial was sponsored by Kyowa Hakko Bio, which makes the Cognizin brand of citicoline, and two of the authors are its employees.
An earlier study gave 60 healthy women aged 40 to 60 250mg, 500mg or placebo for 28 days. Both doses reduced errors on a computerised attention test, the Continuous Performance Test II (McGlade et al., 2012). Four of its eight authors worked for Kyowa Hakko, which supplied the citicoline.
Regulators were not persuaded. In 2024 the European Food Safety Authority reviewed the memory evidence and concluded that “a cause-and-effect relationship has not been established” between citicoline and memory in middle-aged or older adults. It noted that one trial found a benefit at 500mg for 12 weeks, that another at 1g a day for three months did not, and that data from dementia patients did not support the claim either.
Cognitive impairment and stroke
A 2023 meta-analysis of studies in mild cognitive impairment, Alzheimer’s disease and post-stroke dementia found that citicoline improved cognitive scores in every study. Its authors also rated the overall quality as poor, “with significant risk of bias in favor of the intervention” (Bonvicini et al., 2023).
Citicoline is often said to be proven in stroke recovery. It isn’t. Earlier pooled analyses suggested a benefit, but the large ICTUS trial then randomised 2,298 patients to citicoline or placebo and found no difference in recovery at 90 days. A 2020 Cochrane review of 10 trials and 4,281 participants concluded there “may be little to no difference” between citicoline and control on death, disability or functional recovery, based on low-certainty evidence.
Citicoline vs alpha-GPC: the evidence by outcome
🟢 Stronger or replicated human evidence · 🟡 Limited, mixed or preliminary human evidence · 🔴 Not established
Is alpha-GPC safe? Stroke risk and TMAO
The most discussed difference between these two compounds is a safety signal, not a benefit. A South Korean cohort study followed more than 12 million people aged 50 and over, with no prior stroke or Alzheimer’s disease, using national health insurance records from 2009 to 2018. The 108,877 who used alpha-GPC had a higher rate of stroke: an adjusted hazard ratio of 1.43 for any stroke, 1.34 for ischaemic stroke and 1.37 for haemorrhagic stroke. Risk rose with the amount taken (Lee et al., 2021).
A later study from the same national database points the other way. Among 508,107 people newly diagnosed with mild cognitive impairment, the 77% who used alpha-GPC were less likely to progress to dementia, and among those who did not progress, users had fewer strokes: hazard ratios of 0.81 for ischaemic and 0.84 for haemorrhagic stroke (Kim et al., 2025). The authors note they did not analyse dose and relied on diagnostic codes.
Both studies are observational, so neither can show that alpha-GPC caused the difference. Users were identified from health insurance records and may have differed from non-users in ways the adjustments did not capture. The two studies also looked at different groups: the general population over 50 in one, people with diagnosed mild cognitive impairment in the other. The fair reading is that the stroke question is open. No comparable study, in either direction, exists for citicoline.
One proposed explanation is TMAO. The US Office of Dietary Supplements explains that gut bacteria convert some choline to trimethylamine, which the liver turns into trimethylamine-N-oxide (TMAO), “a substance that has been linked to a higher risk of cardiovascular disease.” Alpha-GPC delivers more choline per dose than citicoline, so it supplies more raw material for that pathway. Whether that matters at supplement doses is not known.
Reported side effects of alpha-GPC are mostly mild, including heartburn, headache, insomnia, dizziness and nervousness. Very high choline intakes from all sources can cause a fishy body odour, sweating, vomiting, low blood pressure and liver toxicity; the adult upper limit is 3,500mg of choline a day. If you are over 50, or have high blood pressure, raised cholesterol or a family history of cardiovascular disease, that unresolved question is a reason to discuss alpha-GPC with a doctor first, or to leave it alone. Our nootropic safety guide covers how to weigh signals like this.
Can you take citicoline and alpha-GPC together?
You can, but there is no evidence that you should. The combination has never been tested in a trial, so any claim about what the pair does together is inference. Taking both also raises your total choline intake, and with it whatever risk the choline-to-TMAO pathway carries.
There is a practical cost too. If you start both at once and notice something, good or bad, you cannot tell which compound caused it. If you want to try both, test one on its own first, decide whether it does anything for you, and only then try the other. Our stacking guide explains why untested combinations deserve caution.
🧮 Worked example — choosing between them, step by step
Run the decision in this order. Each step can settle it before you reach the next.
1. Over 50, or any cardiovascular or stroke risk factor? Be cautious with alpha-GPC. One large study found a stroke association in exactly this age group, a second found the opposite, and the question is unresolved. If you still want a choline supplement, citicoline is the one to consider.
2. Is memory in later life the goal? Citicoline has the only relevant trial: 500mg a day for 12 weeks in older adults with memory complaints. It was funded by the maker, and the EU regulator was not convinced, so treat it as a possibility worth testing, not a result to expect.
3. Under 50, healthy, and after a same-day effect on a demanding day? Alpha-GPC has the only single-dose trial, and it is weak: 20 men, one test of three improved. If you try it, use it occasionally, not daily.
4. None of the above? You probably don’t need either. A review of 13 studies found choline supplements did not clearly improve cognition in healthy adults, and eggs, meat, fish and legumes supply choline anyway. If you still want one, default to citicoline.
Named Framework
The NeuroEdge Choline Self-Testing Framework
How to try one of these and find out whether it does anything for you. It lists what the trials used; it is not a prescription.
One at a time
Pick one compound and take nothing else new while you test it. Never start both together.
If you test citicoline
Trials in healthy adults used 250–500mg a day. Its effects were measured after 4 to 12 weeks, so give it 8–12 weeks before judging. Track a short memory or attention task against a two-week baseline.
If you test alpha-GPC
The healthy-adult trial used single doses of 315mg and 630mg, tested an hour later. Because the effect is same-day, compare several on days and off days over a couple of weeks. Check whether your label states active alpha-GPC or 50% powder.
When to stop
If your scores stay inside your normal range, the fair conclusion is no detectable effect for you. If you are over 50 or have cardiovascular risk factors, discuss alpha-GPC with a doctor whatever the result.
For how to set up a baseline and read your own results, see our self-testing method.
Choosing a citicoline or alpha-GPC supplement
Two label checks matter. For alpha-GPC, many products are a 50% powder, so confirm whether the figure on the label is active alpha-GPC or total powder; misreading it halves your dose. For citicoline, Cognizin is the branded form used in both healthy-adult trials, which makes it the closest match to the research. Its maker also funded that research.
Nootropics Depot Alpha GPC — standalone alpha-GPC
Third-party lab tested, with certificates of analysis published by lot. Their capsules list 150mg of alpha-GPC each. A standalone product lets you test alpha-GPC alone.
Mind Lab Pro — citicoline inside a stack
Contains 250mg of Cognizin citicoline per serving, the lower dose from the healthy-adult trials, with every dose disclosed. It also contains ten other ingredients, including Bacopa, Lion’s Mane and Rhodiola, so it cannot tell you what citicoline alone does for you. For a one-compound test, choose a standalone Cognizin product.
These are affiliate links. If you buy through them, NeuroEdge Formula may earn a commission at no extra cost to you. My conclusion above is that many readers need neither compound.
Key takeaways
| → | Neither is well tested in healthy adults. Citicoline has one positive 12-week memory trial in older adults; alpha-GPC has one small single-dose trial. Both were funded by companies that sell the ingredient. |
| → | The head-to-head trials don’t settle it. Three old studies in vascular dementia favoured alpha-GPC on clinical scores, but all used injections and were at high risk of bias. |
| → | “More bioavailable” is not established. The alpha-GPC claim rests on an injection study in 12 volunteers. |
| → | Citicoline is not proven in stroke. The largest trial and the Cochrane review found little or no benefit. |
| → | Alpha-GPC carries an open safety question. A study of 12 million people aged 50 and over linked it to a 43% higher stroke risk; a later study in people with mild cognitive impairment found the opposite. Both are observational. |
| → | If you want one, start with citicoline, test it alone for 8–12 weeks, and stop if you can’t detect an effect. |
Frequently asked questions
Is citicoline the same as alpha-GPC?
No. They are different compounds that both supply choline. Citicoline is the same thing as CDP-choline, and Cognizin is a brand of it. Alpha-GPC is the same thing as choline alfoscerate or L-alpha-glycerylphosphorylcholine. Alpha-GPC carries roughly twice as much choline per milligram; citicoline also supplies cytidine, which the body converts to uridine.
Which is better for memory, citicoline or alpha-GPC?
In people without dementia, only citicoline has been tested for memory: 500mg a day for 12 weeks improved episodic memory in 100 older adults with memory complaints (Nakazaki et al., 2021). That trial was funded by the maker, and the European Food Safety Authority judged the overall memory evidence insufficient. Alpha-GPC has memory-related trials only in people with Alzheimer’s disease or mild cognitive impairment. In the head-to-head dementia trials, the two did not differ on a memory test.
Which is better for focus?
The evidence is thin for both. A single dose of alpha-GPC improved Stroop performance in 20 men but not two other attention and working-memory tests (Kerksick, 2024). Citicoline at 250mg or 500mg a day for 28 days reduced errors on a sustained-attention test in 60 women (McGlade et al., 2012). Both studies had industry involvement. Our L-theanine and caffeine guide covers a different option for focus.
How long does citicoline take to work?
The positive trials measured outcomes after 28 days and after 12 weeks of daily use, so it is not a same-day supplement. Give it 8 to 12 weeks before you judge it. Alpha-GPC is different: its one healthy-adult trial tested people an hour after a single dose.
How much choline do I need without supplements?
The adequate intake is 550mg a day for adult men and 425mg for adult women, from food and supplements combined, with an upper limit of 3,500mg. Eggs, meat, fish, dairy and legumes all supply it. Neither citicoline nor alpha-GPC is needed to meet that figure for most people eating a varied diet.
Get “7 Days to a Sharper Brain” — Free
Peter Benson’s evidence-first starting framework
The habits with the strongest evidence first — sleep, movement, stress and learning — then how to add a single supplement and test whether it actually works for you.
No spam. Unsubscribe anytime.
⚕️ Educational Information, Not Medical Advice
This article is educational and is not medical advice. I’m a cognitive enhancement researcher, not a medical doctor. Both compounds act on cholinergic neurotransmission and may not suit everyone. Observational studies disagree on whether alpha-GPC raises or lowers stroke risk. Consult a qualified healthcare provider before supplementing, particularly if you have cardiovascular risk factors, take anticholinergic or other prescription medication, are pregnant or breastfeeding, or have a neurological condition.
Scientific references
1. Sagaro, G. G., & Amenta, F. (2025). Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Frontiers in Neurology, 16, 1649661. DOI: 10.3389/fneur.2025.1649661
2. Jeon, et al. (2024). Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial. BMC Geriatrics. DOI: 10.1186/s12877-024-05366-7
3. Kerksick, C. M. (2024). Acute alpha-glycerylphosphorylcholine supplementation enhances cognitive performance in healthy men. Nutrients, 16(23), 4240. Link (Funded by NNB Nutrition; the author is a paid adviser to the sponsor.)
4. De Jesus Moreno Moreno, M. (2003). Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics, 25(1), 178–193. PMID: 12637119
5. Nakazaki, E., Mah, E., Sanoshy, K., Citrolo, D., & Watanabe, F. (2021). Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. The Journal of Nutrition. Link (Sponsored by Kyowa Hakko Bio.)
6. McGlade, E., Locatelli, A., Hardy, J., Kamiya, T., Morita, M., Morishita, K., Sugimura, Y., & Yurgelun-Todd, D. (2012). Improved attentional performance following citicoline administration in healthy adult women. Food and Nutrition Sciences, 3, 769–773. DOI: 10.4236/fns.2012.36103 (Four authors employed by Kyowa Hakko Bio.)
7. EFSA Panel on Nutrition, Novel Foods and Food Allergens (2024). ‘Citicoline’ and support of the memory function: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal. DOI: 10.2903/j.efsa.2024.8861
8. Bonvicini, M., et al. (2023). Is citicoline effective in preventing and slowing down dementia? A systematic review and a meta-analysis. Nutrients, 15(2), 386. Link
9. Dávalos, A., et al. (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). The Lancet. PMID: 22691567
10. Martí-Carvajal, A. J., et al. (2020). Citicoline for treating people with acute ischemic stroke. Cochrane Database of Systematic Reviews, CD013066. Cochrane summary
11. Lee, G., et al. (2021). Association of L-α glycerylphosphorylcholine with subsequent stroke risk after 10 years. JAMA Network Open. Link
12. Kim, H.-K., Park, S., Kim, S.-W., et al. (2025). Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: a nationwide longitudinal study in South Korea. The Journal of Prevention of Alzheimer’s Disease. Link
13. Gatti, G., Barzaghi, N., Acuto, G., Abbiati, G., Fossati, T., & Perucca, E. (1992). A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 30(9), 331–335. PMID: 1428296
14. National Institutes of Health, Office of Dietary Supplements. Choline: Fact Sheet for Health Professionals. Updated June 2022. ods.od.nih.gov
15. Alzheimer’s Drug Discovery Foundation. Cognitive Vitality: Alpha-GPC (choline alfoscerate). Updated March 2020. ADDF
Cognitive Enhancement Researcher | 18+ Years Independent Research
Peter is not a clinician; this is educational, not medical advice. This comparison was updated in October 2026 to add the head-to-head meta-analysis, newer citicoline and alpha-GPC trials, and the stroke-risk studies. Read about how NeuroEdge evaluates research.
Last reviewed: October 2026
